BTAI vs HOLX · rev $388.0K vs P/E 32, rev $4.10B
BioXcel Therapeutics Inc (BTAI) versus Hologic Inc (HOLX) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Hologic Inc (HOLX) is a medical instruments & supplies company listed on NASDAQ.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported HOLX revenue for 2025-09-27 was $4.10B. Net income was $565.7M. Revenue was up 1.7% from 2024-09-28 to 2025-09-27. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
BTAI currently screens at market cap $36.1M. HOLX currently screens at market cap $16.97B and trailing P/E 31.5.
Not investment advice. Open the BTAI and HOLX stock pages for the full models.
Not investment advice.